A reversible albumin-binding growth hormone derivative is well tolerated and possesses a potential once-weekly treatment profile.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

A noncovalent albumin binding moiety is attached to the hGH backbone.

Who Took Part

The abstract describes 105 subjects taking part.

PubMed indexes the participants as young adults, adults and middle-aged adults, men only.

Blood samples were drawn for assessment of safety, PK, IGF-1, and IGF binding protein 3 profiles and anti-drug antibodies.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

The subjects were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

Blinding on both sides kept the subjects and researchers unaware of who received Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Some subjects received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.

What Was Measured

Topics PubMed links to this paper include Growth Disorders, Human Growth Hormone, Insulin-Like Growth Factor Binding Protein 3, Insulin-Like Growth Factor I, Lipopeptides and Serum Albumin.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 105 subjects.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2014 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.